It is still unclear why patients who should respond to anti–interleukin-5 therapies do not, noted Anne Reihman, MD, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado.
We’re trying to uncover why patients who should respond to anti–interleukin (IL)-5 therapies do not. Some patients just don’t have a good clinical response to these drugs, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine, prior to this year's CHEST meeting.
Transcript
How will you address the importance of anti–IL-5 therapy failure in patients with severe eosinophilic asthma?
The anti–IL-5 therapies we'll be discussing refer to the biologic therapies that are currently approved for management of severe eosinophilic asthma, and specifically, the drugs that we're talking about are mepolizumab, reslizumab, and benralizumab. These drugs work by blocking molecules along the IL-5 inflammatory pathway, which is involved in eosinophilic production and activation.
While these drugs have been shown to be very helpful in many patients with severe eosinophilic asthma, more recently, we've noticed that there's a group of patients that, though they look like they should be the correct phenotype to respond to these drugs, don't actually have a good clinical response and continue to have asthma exacerbations and symptoms despite initiation of these drugs.
And so it's this group of what we call nonresponders that were really interested in studying at the University of Colorado and kind of are the basis of what I'll be talking about [October 20 at CHEST]. So, I'll be discussing the current data around patients who don't respond to anti–IL-5 therapies.
And I'll preface this by saying that there's not a whole lot of data out there right now, but I will try and cover the current predictors of anti–IL-5 therapy response that we know about, as well as try and discuss some of the predictors that we're looking into, and then discuss possible mechanisms that may be driving anti–IL-5 therapy failure.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More